About the facility

Murdoch University has a nationally and internationally accredited, high throughput medical genomics facility. The facility specialises in medical genomics applications across immunogenomics, immunology, infectious disease, drug hypersensitivity, cancer and Neuropathies. The custom laboratory information management systems, large automation capacity and proprietary analysis and visualisation software allows assay scaling to project needs. The facility has collaborators and clients across the globe, with over 100 active projects.

Our focus is to apply the latest genomics technologies to help researchers prevent and reduce the impact of disease on people and communities around the world, while advancing medical and scientific knowledge in global healthcare.

NATA and ASHI logos

Accreditation

We have the largest array of technologies and workflows in our National Association of Testing Authorities (NATA) accredited scope.  This enables high quality research to meet the strictest international standards and can support biopharma in translational clinical trials to meet international approval body requirements.  Our facility is further accredited by the America Society for Histocompatibility and Immunogenetics (ASHI) demonstrating our commitment to the highest level of sample to data integrity.

Research areas supported

Our translational facility aims to produce clinical practice-altering outcomes for patients with chronic and acute diseases through supporting technologies across our core research and domain areas. We work with researchers and industry groups to meet their advanced genomics needs. We also support all research that has a need for advanced genomics technologies. We can assist you with every stage of your project needs from conception through funding application preparation and guide you through the most appropriate technology to effectively answer your clinical questions.

Learn more about our Laboratory testing service

researchers sequencing data

Sequencing Technologies

Our nucleic acid sequencing platforms include the Illumina NovaSeq 6000, MiSeq (reads up to 2 x 300 bp), Oxford Nanopore Technology (ONT) P2 and Promethion platforms. This includes whole genome sequencing, Exome sequencing, RNA-Seq and CITE-Seq, and other specialised bulk and single cell technologies such as the 10X Chromium X, BD Rhapsody and  the 10 X Visium HD platform for spatial transcriptomics. We perform large numbers of TCR sequencing and targeted gene sequencing assays, including ASHI accredited HLA typing. We are also the WA state provider for Oxford Nanopore Technology (ONT) sequencing for long range sequencing projects and scaffolding (reads can be typically 15kb but can be100Kb plus under special prep conditions).

 

medical researcher

HLA Typing

We support medical researchers where immunology plays a pivotal role in disease with our ASHI accredited Human Leucocyte antigen genes (HLA) typing pipelines. Using our automation and custom LIMS system we have capacity to type large cohorts of samples to unambiguous, high resolution in a single pass. We offer Class 1 HLA A (Exon 2,3), B (Exon 2,3), C (Exon 2,3) and Class II DRB1,3,4,5 (Exon 2), DQB1 (Exon 2,3), DQA1 (Exon 2), DPB1 (Exon2) exon specific typing that resolves Alleles to four or more digit typing levels covering coding region allelic variation.

 

researcher looking at data

Functional assays

We specialise in medical genomics to identify underlying genetics to then test target biomarkers for their clinical utility.  As we discover new genetic signatures we innovate to develop functional assays that can be performed at minimal costs for clinical evaluation.  We are also developing assays relevant to our focus research areas where there is clear clinical knowledge gap for example we are developing new assays to detect protein aggropathies relevant to neurological decline to detect them earlier before the onset of neurological damage and allow early treatment to prevent disease for those likely to be affected.

Scientist conducting test at large automator

Automation platforms

Our large suite of workflow automation platforms are integral to our high throughput workflows and eliminate human handling errors for high throughput needs.  We have suite of Beckman Coulter i7 and FxP platforms, Formulatrix Mantis and ThermoFisher Kingfisher as well as ancillary support platforms for plate based assays , Promega GlowMax and Tecan Hydrospeed systems.  

sequencing data on screen

ERAP Genotyping Assay

Our lab delivers sequence-based typing using the Miseq Illumina platform to target single nucleotide polymorphisms (SNP) for Endoplasmic Reticulum Aminopeptidase 1 and 2 genes. For next-generation sequencing, multiple indexed amplicons are pooled together using our custom LIMS and advanced liquid handling systems, that allows sample tracking and maintains data integrity. Sequencing of the amplicons is followed by identification of the specific SNP variants using in-house developed data visualisation and analysis software.

sequencing machine

KIR Genotyping

We provide gene presence/absence typing for Killer-cell Immunoglobulin-like Receptors (KIR) genes and can also perform more in depth typing of KIR using next-generation sequencing to give full allelic typing across the KIR locus. We have the capacity to type large cohorts of samples to high resolution for 14 gene loci, encoded within a 100-200 Kb region of the Leukocyte Receptor Complex.

researchers using machine

Bulk TCR Assay

The Bulk TCR assay is an adaptation of our single cell TCR assay, based on cell populations or total RNA . This assay is set up for large number of cells (5k-40k) cells directly sorted into our proprietary lysis buffer or from RNA extracted from PBMCs or sorted T cells of interest. The assay also utilises the Smartseq approach using special primers containing Unique Molecular Indexes (UMI’s) to account for PCR duplicates and amplification bias.

Scientist at flow machine

Flow Cytometry

We have invested in flow cytometry to enable sorting of cell populations to aid in genomic analysis and support biomarker discovery.  Our latest flow sorter is the Beckman Coulter Cytoflex SRT that we have contained in a certified Class II hood in a PC2 certified facility to enable sorting of an array of potentially infectious samples.  

Key research domains supported

The key domain areas we support are headed by world leading clinical academic researchers working to translate research and produce clinical practice-altering outcomes for patients and drive the new innovations in the facilities core capabilities. These are headed by research groups that have been instrumental in the development of the facility and its capabilities.

Drug hypersensitivity

 

HIV viral sequencing

 

HIV immunobiology

 

MS immunobiology

 

Myositis immunobiology

 

Cancer & cancer immunogenomics

 

Bacterial genome sequencing

 

Viral genome sequencing

 

Parkinson's Disease

 

Neurogenetics & Psoriasis

 

Motor Neurone Disease

 

Other diseases inc. Dementia

 

Facility Staff

Professor Sulev Koks

Professor Sulev Koks

Laboratory Director

Simon Mallal

Professor Simon Mallal

Clinical Research Professor in Immunology

Elizabeth Phillips

Professor Elizabeth Phillips

Clinical Research Professor in Drug Sensitivity

professor-mark-watson

A. Prof. Mark Watson B.Sc. Ph.D.

Medical Genomics and Facility Manager

abha-chopra

Associate Professor Abha Chopra

Medical Genomics Lead

Ramesh Ram

Dr Ramesh Ram

Senior Bioinformatics and Data Analyst

Don Cooper

Dr Don Cooper

Senior Programmer

Hayley Clark

Hayley Clark

Research Specialist

Imran Ahmad

Mr Imran Ahmad

Accreditation Lead

Linda Choo

Ms Linda Choo

Graduate Research Officer

Melissa Emmanuel

Ms Melissa Emmanuel

Graduate Research Officer

Andrew Gibson

Dr Andrew Gibson

Research Fellow

Sonalia Pinge

Ms Sonali Pinge

Graduate Research Officer

Marjan New

Ms Marjan Rahman Mashhadi

Graduate Research Officer

News from the facility

New partnership to advance camel health and conservation


Murdoch University has entered a landmark partnership with Saudi Arabia's Al Nahdi Family to deliver the world’s most comprehensive genetic map of camels. The initiative marks the first collaboration of its kind between Australia and Saudi Arabia and is set to transform how camel populations are understood, bred and conserved

“Partnering with Murdoch University to unravel the camel pangenome marks the first step in this ambitious and pioneering program,” said Omar Al-Ghamdi, CEO of Al-Shmoul Holding, the subsidiary of the Al Nahdi Family engaged in the project.

“Our goal is to advance camel genomics research, promote long-term preservation through the maintenance of genetic diversity, and strengthen the cultural conversation around camels not only in Saudi Arabia, but globally.” 

The focus of the partnership is to build a high-quality pangenome of the three camel species: Dromedary, Bactrian and wild Bactrian camels.  

These animals are much more than a symbol of desert resilience – they are a cornerstone of cultural heritage and economic livelihood across the Middle East and North Africa.

Globally, there are approximately 41 million camels, yet despite their importance, camel populations face increasing threats from inbreeding, climate stress and loss of genetic diversity.

Professor Sulev Koks, a leading genomics expert, says understanding the genetics of the three camel species will help address some of the risks facing camel populations.

“Our advanced genomics capabilities will deliver the worlds most detailed genetic map of camels, paving the way for management of camel breeding programs and health,” Professor Koks said.

“This research project will shed light on the link between observable traits and underlying genes, with a focus on addressing inbreeding in the context of specific breeding traits such as beauty characteristics, to preserve the cultural and health status of camels.”

“It will also open the door to new opportunities, with the camel pangenome project being first genomic collaboration between Australia and Saudi Arabia.”

The project will be spearheaded by Murdoch University’s multidisciplinary team of genomics, veterinary, bioinformatics and conservation experts, including Professor Koks, Associate Professor Mark Watson, Associate Professor Abha Chopra and Dr Jordan Hampton.

Recent genomic studies in Saudi Arabia have revealed striking differences in genetic diversity across camel populations. Mountainous populations show higher genetic diversity, while coastal populations show signs of genetic isolation and reduced diversity. 

These findings underscore the urgency to develop more robust genomic tools to guide breeding and conservation strategies.

Murdoch’s research team will use advanced sequencing technologies to build a high-resolution pangenome, linking observable traits – such as endurance, disease resistance and even culturally valued beauty characteristics – to their underlying genetic markers. This will help address inbreeding and support sustainable breeding programs that respect both scientific and cultural priorities.

The research is part of a broader One Health research program focused on camels, commissioned by the Al-Nahdi Family. One Health is an integrated approach to tackling health challenges, recognising that the health of people, animals and ecosystems are closely linked and interdependent.

The partnership marks the beginning of a long-term collaboration that intends to extend beyond research into teaching, community engagement and regional development. 

“This project is not just about camels – it’s about connecting science, culture and conservation in a meaningful way,” Professor Koks said. 

Contact us

Location

Building 390
Discovery Way
Murdoch WA 6150